GlassScriptPhysician profile
Misbba Khan
NPI 1205127826
$12,547.02
in general payments reported to CMS, 2019-2025
52 companies · $2,626 in 2025
The $2,626 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.99 · 2020: $128 · 2021: $1,729 · 2022: $1,857 · 2023: $2,990 · 2024: $3,198 · 2025: $2,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,806 · Education: $8.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,806.37 |
| Education | $8.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,037.02 | 2021-2025 | |
| Sk Life Science, INC. | $923.73 | 2021-2025 | Xcopri |
| Acadia Pharmaceuticals INC | $886.68 | 2021-2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $719.80 | 2021-2025 | Austedo Xr, Ajovy, Austedo |
| Lundbeck LLC | $689.02 | 2022-2025 | Vyepti |
| Ucb, INC. | $679.37 | 2023-2025 | Fintepla, Briviact, Rystiggo |
| Neurocrine Biosciences, INC. | $660.55 | 2021-2025 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $564.04 | 2021-2025 | |
| Emd Serono, INC. | $559.45 | 2021-2025 | Mavenclad |
| Pfizer INC. | $530.74 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $422.52 | 2021-2025 | Ultomiris, Soliris |
| Janssen Pharmaceuticals, INC | $380.91 | 2021-2022 | |
| Argenx US, INC. | $350.15 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Mdd US Operations, LLC | $289.34 | 2022-2025 | Gocovri, Gocovri, Apokyn |
| Lilly USA, LLC | $243.49 | 2021-2025 | Emgality, Reyvow, Kisunla |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misbba Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.